Printer Friendly

More OTC weight-loss products deemed illegal.

A diuretic, an antidepressant, and an unapproved stimulant are among the latest undeclared active drug ingredients identified in over-the-counter weight loss products, the Food and Drug Administration has announced.

In a statement, the agency announced that four ingredients--the antidepressant fluoxetine; the diuretic furosemide; fenproporex, an amphetamine derivative and controlled substance that is not approved in the United States; and cetilistat, a drug currently being studied for obesity in the United States and elsewhere--have been detected in OTC weight-loss products sold in the United States.

The illegal products are marketed as Herbal Xenicol, Slim-bionic, and Xsvelten, and have been added to a list compiled by the FDA of OTC weight-loss products that have been found to contain undeclared active pharmaceutical ingredients, which now includes 72 products. Previously identified ingredients include sibutramine, the active ingredient in the FDA-approved obesity drug Meridia; the anti-epileptic drug phenytoin; and rimonabant, an obesity drug that was denied approval in the United States because of neurologic and psychiatric side effects.

Some of the products contain prescription drugs that exceed the maximum recommended dosages. The products are sold on Web sites and in some retail stores and beauty salons. Most of the products appear to be manufactured in China, according to the FDA, which is working on getting these products recalled.

More information, including the full list of products, is available at Serious adverse events associated with these products can be reported to MedWatch at 800-332-1088 or at
COPYRIGHT 2009 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:NEWS FROM THE FDA; over the counter
Author:Mechcatie, Elizabeth
Publication:Internal Medicine News
Article Type:Brief article
Geographic Code:1USA
Date:Apr 15, 2009
Previous Article:Two DNA-based tests for human papillomavirus approved by FDA.
Next Article:FDA reviews bleeding events tied to Xigris.

Related Articles
From prescription to over-the-counter: watered-down warnings.
Groups push to obtain OTC status for Plan B contraceptive.
Feds delay OTC decision for Plan B.
Regulatory watch: pay close attention to current and impending regulatory developments, even if they don't specifically mention supplements.
Orlistat wins approval as OTC weight-loss drug: the thrice-daily drug blocks up to 25% of total fat absorption in the intestine, which is then...
Glaxo and others ask FDA to treat weight loss claims as disease claims.
Weight-loss products found tainted with drugs.
Change we can believe in--new developments in access to emergency contraception.
List of illegal over-the-counter weight-loss products grows.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters